Trial to Evaluate the Safety and Efficacy of Keppra After Conversion to Mono-therapy in Subjects With Partial Epilepsy

Inclusion Criteria: * Diagnosis of epilepsy with partial seizures; * having completed the trial N01031 of Keppra as adjunctive therapy (SKATE); * seizure-free over the last 3 months prior to protocol Visit 1; * 1 concomitant marketed AED at the time of trial entry and throughout the previous trial N01031; * on the clinical judgment of the Investigator, progressive withdrawal of the concomitant AED and conversion to monotherapy with Keppra can be attempted. Exclusion Criteria: * History of suicide attempt, current suicidal ideation, or other serious psychiatric disorders requiring or having required hospitalization or medication within the previous 5 years; * presence of known pseudoseizures within the last year; * presence or history of allergy to the components of Keppra (levetiracetam, lactose, cornstarch, and excipients) or other pyrrolidine derivatives; * felbamate with less than 18 months exposure; * vigabatrin, without visual field assessment as per recommendation of the manufacturer, i.e., every 6 months; * uncountable seizures (clusters) or history of convulsive status epilepticus within the last 5 years.